Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies

Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent graft-versus-host disease (GVHD). There are no random...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomaszewska, Agnieszka, Jagasia, Madan, Beohou, Eric, van der Werf, Steffie, Blaise, Didier, Kanfer, Edward, Milpied, Noel, Reményi, Péter, Ciceri, Fabio, Bourhis, Jean H., Chevallier, Patrice, Solano, Carlos, Socié, Gerard, Bruno, Benedetto, Rambaldi, Alessandro, Castagna, Luca, Kröger, Nicolaus, Corradini, Paolo, Afanasyev, Boris, Ladetto, Marco, Niederwieser, Dietger, Scheid, Christof, Sengeloev, Henrik, Kroschinsky, Frank, Yakoub-Agha, Ibrahim, Schoemans, Helene, Koenecke, Christian, Penack, Olaf, Perić, Zinaida, Greinix, Hildegard, Duarte, Rafael F., Basak, Grzegorz W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884746/
https://www.ncbi.nlm.nih.gov/pubmed/33603743
http://dx.doi.org/10.3389/fimmu.2020.613954

Ejemplares similares

Ejemplares similares